Hypoxia: A key regulator of angiogenesis in cancer

By D. Liao, Richard J. Johnson. Cancer Metastasis Review, 2007

731 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Hypoxia-Inducible Factors in Physiology and Medicine (2012, background): “…al., 2011), cell immortalization, epithelial-mesenchymal transition (Mak et al., 2010), genetic instability (Huang et al., 2007), vascularization (Liao and Johnson, 2007), glucose metab- olism (Luo et al., 2011), pH regulation (Swietach et al., 2007), immune evasion (Lukashev et al., 2007),…”
Defining the Role of Hypoxia-Inducible Factor 1 in Cancer Biology and Therapeutics (2009, neutral): “…HIF1-dependent manner encode proteins from A to Z that have key roles in every critical aspect of cancer biology (Table 5), including angiogenesis (Liao and Johnson, 2007), cell survival, chemotherapy and radiation resistance (Moeller et al., 2007), genetic instability (Bindra et al., 2007),…”
Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. (2008, background): “[132] D.”
The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. (2009, neutral): “This process is strongly controlled by hypoxia-dependent, tissue-derived proangiogenic signals, such as vascular endothelial growth factor (VEGF), which binds to cognate receptors in the endothelium (Carmeliet, 2005; Liao and Johnson, 2007).”